Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals

Journal of Clinical Lipidology

Volumn 9, Issue 5, 2015, Pages 658-663

  Ariel, Danit ^a   Kim, Sun H ^a   Liu, Alice ^a   Abbasi, Fahim ^a   Lamendola, Cindy A ^a   Grove, Kaylene ^a   Tomasso, Vanessa ^a   Reaven, Gerald M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease risk; Insulin resistance; Lipid and or lipoprotein abnormalities; Prediabetes; Salsalate

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SALSALATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOPROTEIN; SALICYLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEARTBURN; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TINNITUS; TRIACYLGLYCEROL BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD; MIDDLE AGED;

APOPROTEINS; ATHEROSCLEROSIS; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; MALE; MIDDLE AGED; OBESITY; SALICYLATES;

EID: 84941421286     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.06.009     Document Type: Article

References (21)

1. A.B. Goldfine, V. Fonseca, K.A. Jablonski, and et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial Ann Intern Med 152 6 2010 346 357
2. E. Faghihimani, A. Aminorroaya, H. Rezvanian, P. Adibi, F. Ismail-Beigi, and M. Amini Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes Acta Diabetol 50 4 2013 537 543
3. A.B. Goldfine, V. Fonseca, K.A. Jablonski, and et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial Ann Intern Med 159 1 2013 1 12
4. A.B. Goldfine, P.R. Conlin, F. Halperin, and et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance Diabetologia 56 4 2013 714 723
5. S.H. Kim, A. Liu, D. Ariel, and et al. Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study Diabetes care 37 7 2014 1944 1950
6. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 6 1972 499 502
7. S.S. Martin, M.J. Blaha, M.B. Elshazly, and et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications J Am Coll Cardiol 62 8 2013 732 739
8. M. Miller, N.J. Stone, C. Ballantyne, and et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 20 2011 2292 2333
9. H.E. Bays, P.H. Jones, W.V. Brown, and T.A. Jacobson National Lipid Association Annual Summary of Clinical Lipidology 2015 J Clin Lipidol 8 6 Suppl 2014 S1 S36
10. M.H. Davidson, C.M. Ballantyne, T.A. Jacobson, and et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 5 2011 338 367
11. T.A. Jacobson, M.K. Ito, K.C. Maki, and et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary J Clin Lipidol 8 5 2014 473 488
12. K.R. Kulkarni Cholesterol profile measurement by vertical auto profile method Clin Lab Med 26 4 2006 787 802
13. J.W. Chu, F. Abbasi, K.R. Kulkarni, and et al. Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the vertical auto profile-II methodology Clin Chem 49 6 Pt 1 2003 1014 1017
14. S.W. Shen, G.M. Reaven, and J.W. Farquhar Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes J Clin Invest 49 12 1970 2151 2160
15. M.S. Greenfield, L. Doberne, F. Kraemer, T. Tobey, and G. Reaven Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp Diabetes 30 5 1981 387 392
16. D. Pei, C.N. Jones, R. Bhargava, Y.D. Chen, and G.M. Reaven Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test Diabetologia 37 8 1994 843 845
17. J.W. Knowles, T.L. Assimes, P.S. Tsao, and et al. Measurement of insulin-mediated glucose uptake: direct comparison of the modified insulin suppression test and the euglycemic, hyperinsulinemic clamp Metabolism 62 4 2013 548 553
18. M.J. Stampfer, R.M. Krauss, J. Ma, and et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction JAMA 276 11 1996 882 888
19. B. Lamarche, A. Tchernof, S. Moorjani, and et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study Circulation 95 1 1997 69 75
20. F.M. Sacks, and H. Campos Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal J Clin Endocrinol Metab 88 10 2003 4525 4532
21. P.T. Williams, X.Q. Zhao, S.M. Marcovina, J.D. Otvos, B.G. Brown, and R.M. Krauss Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease Atherosclerosis 233 2 2014 713 720